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Strategies to address the shortcomings of 
commonly used advanced chronic heart 
failure descriptors to improve recruitment 
in palliative care research: A parallel  
mixed-methods feasibility study
Pauline M Kane1, Fliss EM Murtagh1, Karen R Ryan2,3,  
Mary Brice4, Niall G Mahon3, Brendan McAdam5,  
Regina McQuillan2,5, Geraldine O’Gara5, Caroline Raleigh5, 
Cecelia Tracey3, Christine Howley3, Irene J Higginson1  
and Barbara A Daveson1; on behalf of BuildCARE*
Abstract
Background: Recruitment challenges contribute to the paucity of palliative care research with advanced chronic heart failure patients.
Aim: To describe the challenges and outline strategies of recruiting advanced chronic heart failure patients.
Design: A feasibility study using a pre–post uncontrolled design.
Setting: Advanced chronic heart failure patients were recruited at two nurse-led chronic heart failure disease management clinics 
in Ireland
Results: Of 372 patients screened, 81 were approached, 38 were recruited (46.9% conversion to consent) and 25 completed 
the intervention. To identify the desired population, a modified version of the European Society of Cardiology definition was used 
together with modified New York Heart Association inclusion criteria to address inter-study site New York Heart Association 
classification subjectivity. These modifications substantially increased median monthly numbers of eligible patients approached 
(from 8 to 20) and median monthly numbers recruited (from 4 to 9). Analysis using a mortality risk calculator demonstrated 
that recruited patients had a median 1-year mortality risk of 22.7 and confirmed that the modified eligibility criteria successfully 
identified the population of interest. A statistically significant difference in New York Heart Association classification was found in 
recruited patients between study sites, but no statistically significant difference was found in selected clinical parameters between 
these patients.
Conclusion: Clinically relevant modifications to the European Society of Cardiology definition and strategies to address New York 
Heart Association subjectivity may help to improve advanced chronic heart failure patient recruitment in clinical settings, thereby 
helping to address the paucity of palliative care research this population.
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Introduction
Chronic heart failure (CHF) is a progressive condition with a 
comparable mortality rate to cancer,1 predominantly affect-
ing older adults with multi-morbidity.2 It is a condition with 
a risk of sudden or premature death3 and can necessitate 
therapeutic decision-making between life-prolonging treat-
ments and quality of life.4 Older CHF patients with multi-
morbidity particularly require a holistic patient-centred 
approach to care5 to facilitate therapeutic decision-making 
around quality of life versus life prolongation.6 Many CHF 
patients experience palliative needs. A palliative care needs 
assessment presents one way to integrate palliative care into 
CHF management and potentially improve patient care.7
Recruitment challenges contribute to the paucity of 
CHF palliative care needs assessment research. Recruitment 
is difficult for many reasons: advanced CHF is difficult to 
define;8 it has unclear inconsistent descriptive nomencla-
ture;9 it has a variable progression rate10 and unpredictable 
prognosis;11 there is high patient attrition due to illness bur-
den and high mortality;12 and gate-keeping often occurs.13
This article describes recruitment challenges experi-
enced in a feasibility study of a palliative-specific patient-
reported outcome measure (PROM) intervention and how 
these challenges were addressed. It provides recruitment 
solutions for future studies involving CHF patients.
Methods
Study design
This parallel mixed-methods feasibility study14 involved a 
pre–post uncontrolled longitudinal study design. This 
study examined the feasibility and acceptability of the 
palliative-specific PROM intervention to improve identifi-
cation and management of palliative symptoms and con-
cerns in advanced CHF patients. As part of this feasibility 
study, we examined our ability to recruit participants.
Setting
Study settings were CHF disease management clinics in 
two tertiary referral centres in Ireland led by heart failure 
nurses (HFN) and supported by CHF physicians.
Inclusion criteria development
Inclusion criteria (Figure 1) were developed by the study 
lead (P.M.K.), the HFNs and the research team. The cri-
teria were informed by the advanced CHF definition in 
the 2012 European Society of Cardiology (ESC) Heart 
Failure Association position statement11 and by the ESC 
palliative care position statement.15,16 Although not 
included in the 2012 ESC definition,11 a definition of 
Heart Failure with preserved Ejection Fraction (HFpEF) 
as per the 2016 ESC definition17,18 was included in the 
criteria at the HFNs’ recommendation as this constituted 
over 50% of their patient population. Of note, HFpEF is 
included in the 2016 ESC definition which was not pub-
lished at the time of this study.18 Once recruitment com-
menced, P.M.K. and the HFNs frequently reviewed the 
inclusion criteria. Subsequently, the requirement for a 
heart failure–related hospitalisation in the preceding 6 
months was removed because it was not appropriate in a 
What is already known about the topic?
•• Recruitment of advanced chronic heart failure (CHF) patients is challenging due to high illness burden.
•• Palliative care needs assessment research is lacking for advanced CHF patients.
What this paper adds?
•• The New York Heart Association (NYHA) Functional Classification does not capture the fluctuating health status of 
advanced CHF patients.
•• The NYHA classification as a stand-alone inclusion criterion can act as a recruitment barrier to palliative care studies.
•• The 2012 European Society of Cardiology definition of advanced CHF used in this study is too narrow to reflect the 
multi-morbidity and fluctuating status frequently associated with advanced CHF.
Implications for practice, theory or policy
•• The 2016 European Society of Cardiology definition better reflects indicators of worsening CHF and has removed 
NYHA as a criterion for end-of-life care.
•• More emphasis is required on a palliative care approach throughout the disease trajectory in this definition.
•• Strategies to address NYHA subjectivity may help to improve advanced CHF patient recruitment in clinical settings includ-
ing the American College of Cardiology Foundation (ACC)/American Heart Association (AHA) CHF staging system.
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setting where nurse-led clinics work to avoid heart fail-
ure–related admissions.
Ethics
Ethical approval was obtained from the Research Ethics 
Committees: Ref: 13/70, Ref: 1/378/1579 and Ref: 
BDM/13/14-25. Written informed consent was obtained 
from participants.
Intervention
The intervention involved administration of the Integrated 
Palliative care Outcome Scale (IPOS)19 together with 
HFN training. Training involved patient-centred educa-
tion, the role of PROMs to facilitate patient-centred care, 
training in IPOS interpretation and use in consultation. 
The IPOS is a 20-item questionnaire measuring patient’s 
physical symptoms, psychological, emotional, spiritual, 
information and support needs.
Strategies to address recruitment challenges
To increase engagement, HFNs and service users helped 
develop study participant documentation. Posters 
advertising the study were placed in study sites. Screening 
logs were developed with HFN input. HFNs reviewed the 
clinical roster daily to identify eligible patients and com-
pleted weekly logs recording: numbers of screened and 
eligible patients, number approached, number recruited, 
reasons why patients were deemed ineligible, were not 
approached or declined participation.
Patients were given information on three occasions 
before written consent was requested. HFNs were pro-
vided with summary cards outlining key study points for 
eligible patients.20 They provided patients with documen-
tation and obtained permission for the researcher to explain 
the study in depth. Potential participants returned signed 
consent forms. The researcher arranged a telephone 
appointment to complete the first set of questionnaires, 
which otherwise acted as a patient reminder for those who 
had not returned consent forms.
Analysis
Analysis of recruited patients was undertaken to deter-
mine whether the inclusion criteria modifications identi-
fied the same population (advanced CHF patients). We 
applied the Meta-analysis Global Group in Chronic Heart 
Failure (MAGGiC) heart failure mortality risk score21 to 
Figure 1. Adaptation of the European Society of Cardiology’s advanced chronic heart failure definition for the study inclusion criteria.
CHF: chronic heart failure; HF: heart failure; NYHA: New York Heart Association; LVEF: left ventricular ejection fraction; PCWP: pulmonary capil-
lary wedge pressure; RAP: right atrial pressure; BNP: brain natriuretic peptide; NT: Nterminal; 6-MWT: 6-minute walk test; VO2: oxygen consump-
tion; CRT: cardiac resynchronisation therapy; HFrEF: Heart Failure with Reduced Ejection Fraction; HFpEF: Heart Failure with Preserved Ejection 
Fraction; HF CNS: Heart Failure Clinical Nurse Specialist.
*Essential inclusion criteria.
†Source: Metra et al.15
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calculate the median 1-year mortality risk for each recruited 
patient21 to determine participant homogeneity. The 
Kruskal–Wallis Test was applied to selected clinical mark-
ers to test for difference between participants assigned dif-
ferent New York Heart Association (NYHA) classes.
Results
Recruitment
Patients were recruited from September 2014 until 
February 2015 at the nurse-led clinics. Of 372 patients 
screened, 81 were approached, 38 were recruited (46.6% 
conversion to consent22) and 25 completed the IPOS. 
Figure 2 shows the modified CONSORT flow diagram.23
Recruited patients’ characteristics
Table 1 reports the demographic and clinical data for par-
ticipants. To ensure a representative sample of advanced 
CHF patients, comparison was made with data from 
Pocock et al.’s21 study. This demonstrated comparability 
with deceased patient data (Table 1).
A review of recruitment activity showed that Site A 
recruited low numbers. Two issues were identified. First, 
patients were deemed too unwell to be approached for 
recruitment. Second, patients frequently declined to par-
ticipate. On exploration, a difference was identified in the 
manner in which Site A and Site B applied NYHA classi-
fication. Site A patients classified as NYHA III frequently 
had lower functional ability than Site B patients classified 
as NYHA III. Where Site B classified patients as NYHA 
III, Site A classified comparable patients as NYHA II. 
This resulted in Site A identifying a more unwell popula-
tion of NYHA III patients than Site B limiting recruit-
ment. To ensure recruitment homogeneity, eligibility 
criteria were modified to allow Site A to recruit patients 
who were currently classified as NYHA II, who had been 
NYHA III/IV in the previous 6 months. This resulted in an 
increase in the total median number approached monthly 
from 8 to 20, and in the median numbers recruited 
monthly, from 4 to 9 (Figure 3).
The MAGGIC mean integer mortality risk score was 
27.9 ± 4.9 (median: 29.0) with a mean 1-year mortality 
proportional risk of 22.2 ± 9.2 (median: 22.7). A Kruskal–
Wallis Test demonstrated no statistical difference in cre-
atinine levels between patients assigned NYHA II (n = 8) 
or assigned NYHA III/IV (n = 17), χ2 (20, n = 25) = 17.75, 
p = 0.63 between the two sites (Table 2). A Kruskal–
Wallis Test demonstrated no statistical difference in 
1-year mortality risk between patients assigned NYHA II 
(n = 8) or assigned NYHA III/IV (n = 17), χ2 (12, 
n = 25) = 17.75, p = 0.12 between the two sites (Table 2). 
Median scores for creatinine and 1-year mortality were 
117 and 14.7 for the NYHA II group and 122 and 24.8 for 
the NYHA III/IV group.
Figure 2. Modified CONSORT flow diagram showing patient recruitment.
ACHF: advanced chronic heart failure.
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Kruskal–Wallis Test revealed a statistically significant 
difference in NYHA classification across sites (Site A, 
n = 10; Site B, n = 15), χ2 (1, n = 25), 16.94, p = 0.0001 (Table 
3). The median NYHA class for Site B was 3, that is, NYHA 
III, while in Site A, it was 2, that is, NYHA II. There was no 
statistical significant difference in systolic blood pressure, 
Charlson comorbidity index,24 creatinine or 1-year mortal-
ity risk21 between patients recruited at each site (Table 3).21
Discussion
This study highlights that commonly used advanced CHF 
descriptors do not comprehensively identify advanced 
CHF patients, necessitating a different approach in pallia-
tive care study inclusion criteria development. The 2012 
ESC advanced CHF definition15 which we used to inform 
our inclusion criteria (Figure 1) was too narrow to capture 
fluctuating health status.25 Patients who were initially too 
unwell to be approached were too well post-treatment to 
fulfil inclusion criteria based on this definition. This study 
demonstrates that the subjectivity of the application of 
NYHA classification and heterogeneity of this population 
mean using NYHA as a stand-alone inclusion criterion 
risks excluding patients from studies and reducing gener-
alisability. Restricting participation to NYHA III/IV 
excludes more stable patients classified as NYHA II at the 
time of study recruitment, yet these patients may have pal-
liative care needs.
The NYHA classification was designed to classify heart 
disease patients based on functional capacity, in the 
absence of more objective evidence.26,27 Its lack of inter-
rater reliability,28 poor reproducibility and validity have 
been acknowledged.29 Yet it continues to play a role in 
inclusion criteria11,30 and as a determinant for palliative 
care access.31 To address NYHA limitations, the American 
College of Cardiology Foundation (ACC)/American Heart 
Association (AHA) CHF staging system describes CHF in 
stages of disease progression,32 while contextualising 
NYHA class to provide a more objective and reliable 
approach to identification (Figure 4).32
Table 1. Comparative demographic and clinical patient data between this feasibility study and living patient data from Pocock 
et al.’s21 study.
Recruited participants 
to this study (n = 25)
Living patient data from Pocock 
et al.’s21 study (n = 23,521)
Deceased patient data from 
Pocock et al.’s21 study (n = 15,851)
Age (years), mean ± SD 75.7 ± 9.2 64.3 ± 11.8 71.9 ± 10.9
Male (%) 56.0 69.0 65.1
Body mass index (kg/m2), mean ± SD 27.1 ± 4.8 27.5 ± 5.1 26.0 ± 5.0
Current smoker (%) 4.0 34.2 29.0
Ejection fraction (%) 39.2 36.6 ± 14.0 33.6 ± 14.0
Systolic blood pressure (mmHg) 118.6 ± 19.1 131.0 ± 21.8 130.5 ± 25.6
Diastolic blood pressure (mmHg) 66.5 ± 9.7 77.7 ± 12.1 75.5 ± 13.5
Heart failure duration ⩾ 18 months (%) 80.0 48.8 49.7
NYHA class (%)
II 32.0 53.8 37.1
III 64.0 31.3 42.8
IV 4.0 4.1 13.4
Creatinine (µmol/L) 129.7 ± 46.8 109.4 ± 55.8 126.9 ± 58.4
Medical history (%)
Diabetes mellitus 32.0 20.6 25.7
MI 48.0 45.6 43.6
Atrial fibrillation 68.0 17.8 23.5
Stroke 32.0 6.2 12.2
COPD 32.0 5.7 17.0
Hypertension 56.0 41.3 39.3
Ischaemic heart disease 68.0 52.9 51.8
CABG 48.0 15.4 13.9
PCI 36.0 11.7 7.9
Depression 20.0 –  
Medications (%)
Beta-blocker 100 40.4 24.4
ACE-I/ARB 80.0 71.3 60.5
CRT-D 48.0 – 4.3
ACE-I: angiotensin-converting-enzyme inhibitor; CRT-D: cardiac resynchronisation therapy defibrillator; SD: standard deviation; NYHA: New York 
Heart Association; MI: Myocardial Infarction; COPD: Chronic Obstructive Pulmonary Disease; CABG: Coronary Artery Bypass Grafting;  
PCI: Percutaneous Coronary Intervention; ARB: Angiotensin II Receptor Blocker.
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CHF is characterised by symptom volatility meaning 
NYHA class can change over short time periods33 affect-
ing eligibility for study inclusion criteria applied at a 
single time-point. We extended recruitment to patients 
classified as NYHA II, with a NYHA III/IV history. 
There was no statistical difference in clinical parame-
ters between these patients and those recruited as class 
NYHA III/IV. Limiting recruitment to NYHA III/IV 
excludes symptomatically stable NYHA II patients who 
have been NYHA III/IV previously and are at risk of 
Figure 3. Number of patients recruited per month before and after change in NYHA inclusion criteria.
*Patients who were currently assigned NYHA II functional class but had recently been assigned NYHA functional class III or IV were included.
Table 2. Kruskal–Wallis Test for difference between NYHA II or NYHA III/IV grade using grouping variables Creatinine and 1-year 
mortality risk score.
Test variable NYHA II or NYHA III/IV
Grouping variable Creatinine 1-year mortality risk score
df 20 12
Chi-square 17.38 17.75
Degree of freedom 20 12
Asymptotic significance 0.63 0.12
NYHA: New York Heart Association.
Table 3. Kruskal–Wallis Test for difference between Site-A participants and Site-B participants using grouping variables: creatinine 
and 1-year mortality risk score NYHA II or NYHA III/IV grade.
Test variable Grouping variable Chi-square Degree of 
freedom
Asymptotic 
significance
Site A or Site B NYHA II or NYHA III 16.94 1 0.0001
Systolic blood pressure 21.3 22 0.5
Charlson comorbidity score 1.67 3 0.64
Creatinine 18.0 20 0.59
1-year mortality risk score 5.42 7 0.61
NYHA: New York Heart Association.
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deterioration from underlying heart disease or multi- 
morbidity.3
A limitation of this study is that it may not reflect CHF 
patients without access to nurse-led clinics. Additionally, 
we did not conduct quality assurance of the HFNs’ assess-
ment of eligibility and information provision to patients.
Conclusion
The recently updated 2016 ESC definition18 better reflects 
the interplay of comorbidities with CHF but more empha-
sis is required on a palliative care approach throughout the 
disease trajectory. Despite its shortcomings, NYHA clas-
sification is widely used. Strategies to address NYHA sub-
jectivity including the ACC/AHA CHF staging system 
may improve advanced CHF patient recruitment and 
advance palliative care research.
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